New Medication Approved for Treatment of Overactive Bladder (OAB)

Myrbetriq (mirabegron) was approved by the FDA for symptoms of overactive bladder (OAB) including urge urinary incontinence, urgency and frequency. Myrbetriq was studied for 10 years in more than 10,000 individuals before approval by the FDA on June 28, 2012.

Antimuscarinics traditionally used to treat OAB work by binding to muscarinic receptors in the bladder, inhibiting involuntary bladder contractions.

The mechanism of action for Myrbetriq is activation of beta-3 adrenergic receptors, making it the first oral OAB medication to work by relaxing the detrusor muscle of the bladder. Bladder relaxation allows for increased bladder capacity, decreasing symptoms of urinary frequency.

Unlike other anticholinergic medications, Myrbetriq does not have side effects of dry mouth or constipation. Myrbetriq may also be used in patients with urinary retention, as it has not been shown to cause or increase urinary retention.

A thorough history and physical is essential in finding the best treatment for your symptoms.